Kyowa Hakko Kirin Co., Limited

Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Koygo Co., Ltd.

Tomoyuki Kanda

Junichi Shimada

Shunji Ichikawa

Takashi Sawada

Fumio Suzuki

Yoshihisa Kuwana

Shizuo Shiozaki

Noriaki Uesaka

Hironori Imma

Shinichi Uchida

Koji Yamada

Michio Ichimura

Hiromi Nonaka

Shigeto Kitamura

Joji Nakamura

Nobuaki Koike

Hiroshi Tsumuki

Junichi Ikeda

Junya Kase

Masako Kurokawa

Naoto Osakada

Akiko Nakamura

Uesaka Noriaki

Provided are an agent for the treatment and/or prophylaxis of a movement disorder, the agent for the treatment and/or prophylaxis wherein the movement disorder is extrapyramidal syndrome, the agent for the treatment and/or prophylaxis wherein the movement disorder is bradykinesia, gait disturbance, dystonia, dyskinesia or tardive dyskinesia, the agent for the treatment and/or prophylaxis wherein the movement disorder is a side effect of L-DOPA and/or dopamine agonist therapy, and the like, each containing a thiazole derivative represented by the formula (I) wherein Rrepresents aryl and the like, and Rrepresents pyridyl or the like, or a pharmaceutically acceptable salt thereof as an active ingredient. 

Therapeutic agent for motor disorders

The problem is to provide a method that can quickly and efficiently evaluate the toxicity of human cerebrospinal fluid (CSF) with small amounts of human CSF. The problem is solved by a method comprising administering human CSF into the cerebral ventricle of a rodent such as a mouse, and evaluating the cognitive function of the rodent by using a behavioral pharmacological technique.

Method for measuring toxicity of human CSF

Provided are therapeutic and/or preventive agents for migraine which comprise, as an active ingredient, a compound having a selective adenosine Areceptor antagonistic activity or a pharmaceutically acceptable salt thereof; therapeutic and/or preventive agents for migraine which comprise, as an active ingredient, a compound having a selective adenosine Areceptor antagonistic activity, which has an affinity for the adenosine Areceptor 10 times or higher than that for the adenosine Areceptor, or a pharmaceutically acceptable salt thereof; and the like.

Therapeutic agent for migraine

Provided are an agent for the treatment and/or prophylaxis of a mood disorder comprising, as an active ingredient, a thiazole derivative represented by the formula (I) wherein Rrepresents aryl or the like, and Rrepresents pyridyl or the like, or a pharmaceutically acceptable salt thereof, and the like. 

Therapeutic agent for mood disorders

&lsqb;1,2,4&rsqb;triazolo&lsqb;1,5-c&rsqb;pyrimidine derivatives

&lsqb;1,2,4&rsqb;Triazolo&lsqb;1,5-c&rsqb;pyrimidine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof are provided, which have adenosine A,receptor antagonism and are useful for the treatment or prevention of various diseases induced by hyperactivity of adenosine A,receptors (for example, Parkinson's disease or senile dementia):

&lsqb;1,2,4&rsqb; triazolo &lsqb;1,5-C&rsqb; pyrimidine derivatives

Therapeutic purine agents for parkinson's disease

Growing community of inventors

Shizuoka, Japan

Tomoyuki Kanda